Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 247

1.
2.

[Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].

Jegu J, Tretarre B, Grosclaude P, Rebillard X, Bataille V, Malavaud B, Iborra F, Salama G, Rischmann P, Villers A.

Prog Urol. 2009 Jul;19(7):487-98. doi: 10.1016/j.purol.2009.03.001. Epub 2009 Apr 28. French.

PMID:
19559380
3.
4.

Screening with prostate specific antigen and metastatic prostate cancer risk: a population based case-control study.

Kopec JA, Goel V, Bunting PS, Neuman J, Sayre EC, Warde P, Levers P, Fleshner N.

J Urol. 2005 Aug;174(2):495-9; discussion 499.

PMID:
16006879
5.

Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).

Schröder FH.

Can J Urol. 2005 Feb;12 Suppl 1:2-6; discussion 92-3. Review.

PMID:
15780157
6.

Risk of dying from prostate cancer in men randomized to screening: differences between attendees and nonattendees.

Bergdahl AG, Aus G, Lilja H, Hugosson J.

Cancer. 2009 Dec 15;115(24):5672-9. doi: 10.1002/cncr.24680.

7.

Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.

Andriole GL, Levin DL, Crawford ED, Gelmann EP, Pinsky PF, Chia D, Kramer BS, Reding D, Church TR, Grubb RL, Izmirlian G, Ragard LR, Clapp JD, Prorok PC, Gohagan JK; PLCO Project Team..

J Natl Cancer Inst. 2005 Mar 16;97(6):433-8.

PMID:
15770007
8.

Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.

Schröder FH, Bangma CH, Roobol MJ.

Eur Urol. 2008 May;53(5):901-8. doi: 10.1016/j.eururo.2008.01.048. Epub 2008 Jan 28.

PMID:
18262712
9.

Second round results of the Finnish population-based prostate cancer screening trial.

Mäkinen T, Tammela TL, Stenman UH, Määttänen L, Aro J, Juusela H, Martikainen P, Hakama M, Auvinen A.

Clin Cancer Res. 2004 Apr 1;10(7):2231-6.

10.

Tumor characteristics in a population-based prostate cancer screening trial with prostate-specific antigen.

Mäkinen T, Tammela TL, Hakama M, Stenman UH, Rannikko S, Aro J, Juusela H, Määttänen L, Auvinen A.

Clin Cancer Res. 2003 Jul;9(7):2435-9.

11.

Extent of prostate-specific antigen contamination in the Spanish section of the European Randomized Study of Screening for Prostate Cancer (ERSPC).

Luján M, Páez A, Pascual C, Angulo J, Miravalles E, Berenguer A.

Eur Urol. 2006 Dec;50(6):1234-40; discussion 1239-40. Epub 2006 May 3.

PMID:
16704893
12.
13.

Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC).

Schröder FH, Hugosson J, Carlsson S, Tammela T, Määttänen L, Auvinen A, Kwiatkowski M, Recker F, Roobol MJ.

Eur Urol. 2012 Nov;62(5):745-52. doi: 10.1016/j.eururo.2012.05.068. Epub 2012 Jun 7.

PMID:
22704366
14.

The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.

Wilt TJ, Brawer MK, Barry MJ, Jones KM, Kwon Y, Gingrich JR, Aronson WJ, Nsouli I, Iyer P, Cartagena R, Snider G, Roehrborn C, Fox S.

Contemp Clin Trials. 2009 Jan;30(1):81-7. doi: 10.1016/j.cct.2008.08.002. Epub 2008 Aug 23.

PMID:
18783735
15.

[Prostate cancer screening].

Villers A, Rébillard X, Soulié M, Davin JL, Coloby P, Moreau JL, Mejean A, Irani J, Coulange C, Mangin P; French Association of Urology..

Prog Urol. 2003 Apr;13(2):209-14. French.

PMID:
12765053
17.

Why do men refuse or attend population-based screening for prostate cancer?

Nijs HG, Essink-Bot ML, DeKoning HJ, Kirkels WJ, Schröder FH.

J Public Health Med. 2000 Sep;22(3):312-6.

PMID:
11077903
18.

Prostate-specific antigen screening and mortality from prostate cancer.

Marcella SW, Rhoads GG, Carson JL, Merlino F, Wilcox H.

J Gen Intern Med. 2008 Mar;23(3):248-53. doi: 10.1007/s11606-007-0479-7. Epub 2008 Jan 3.

19.

hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.

Raaijmakers R, de Vries SH, Blijenberg BG, Wildhagen MF, Postma R, Bangma CH, Darte C, Schröder FH.

Eur Urol. 2007 Nov;52(5):1358-64. Epub 2007 Apr 20.

PMID:
17499425
20.

The Japanese guideline for prostate cancer screening.

Hamashima C, Nakayama T, Sagawa M, Saito H, Sobue T.

Jpn J Clin Oncol. 2009 Jun;39(6):339-51. doi: 10.1093/jjco/hyp025. Epub 2009 Apr 4.

PMID:
19346535

Supplemental Content

Support Center